GLP-1 Receptor Agonist Medications Clinical Trials

• Introduction

Numerous GLP-1 receptor agonist medications exist that include RYBELSUS®, OZEMPIC® and WEGOVY®. These medications have Semaglutide as their active ingredient. Although there are specific FDA-approved indications that are available from reviewing the Prescriber Information ("PI") included in the labeling of the respective medications, you can often look at past or ongoing clinical trials for information concerning possible off-label uses of a drug.

Background

To search for clinical trials, you can look at numerous websites including, but not limited to www.fda.gov. In general, clinical trials are research studies in which people volunteer to help find answers to specific questions concerning treatments for various conditions. When carefully conducted, they are the safest and fastest way to find new treatments and ways to improve health. Clinical trials are conducted according to a plan, called a protocol, which describes: (1) the types of patients who may enter the study, (2) the schedules of tests and procedures, (3) the drugs involved, (4) the dosages, or amount of the drug, (5) the length of the study, and (6) what the researchers hope to learn from the study. Volunteers who participate in the study must agree to the rules and terms outlined in the protocol. Similarly, researchers, doctors, and other health professionals who conduct and manage clinical trials must follow strict rules set by the FDA. These rules make sure that those who agree to participate are treated as safely as possible. To learn more about the basics of clinical trial participation, you can review information on www.nih.gov.

• Conclusion

Reviewing specific past or ongoing clinical trials can generally provide information on ways a drug might be able to be used in the future. If you go to www.clinicaltrials.gov and search "Semaglutide", you will see many clinical trials ongoing. By viewing the different types of clinical trials being conducted, it appears that Semaglutide, and possibly other GLP-1 receptor agonist medications, could have very broad potential uses worldwide

RYBELSUS®, OZEMPIC® and WEGOVY® are all registered trademarks of Novo Nordisk A/S. ClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The National Library of Medicine (NLM) maintains the website. The study sponsor or investigator submits information about their study to ClinicalTrials.gov and is responsible for the safety, science, and accuracy of any study they list.